Meta CEO Zuckerberg Says AI Agent Development Has Slowed Despite Massive AI Investment 
Kuaishou Stock Jumps as Kling AI Secures $2 Billion Funding Round 
Apple Challenges India Antitrust Probe, Says CCI Copied Rivals’ Claims in App Store Case 
US Egg Producers Settle Price Manipulation Probe, Agree to Pay $3.3 Million and Donate 53 Million Eggs 
California Court Dismisses Trump Administration Lawsuit Against Los Angeles Sanctuary Policy 
Samsung to Invest $90 Billion in South Korea to Expand AI Chip, Display, and Battery Production 
Anthropic Tightens AI Access Controls After Reports of China-Based Workarounds 
Bank of America Upgrades T-Mobile to Buy, Says LEO Satellite Fears Are Overdone 
Switch Seeks $2 Billion Funding at Nearly $50 Billion Valuation Ahead of Potential IPO 
US Supreme Court Strikes Down Hawaii Gun Carry Law on Private Property 
Foxconn Q2 Revenue Surges Nearly 40% on Strong AI Server Demand 
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case 
Trump Administration to Launch Voluntary AI Standards for Frontier Models 
Apple Expands iPhone Lineup, Boosts Foldable iPhone Production Plans Through 2027 
US Appeals Court Limits ICE Detention Without Bond Hearings After 90 Days 
A federal jury in California has ordered Apple to pay $634 million to Masimo after finding that features in the Apple Watch infringed on the medical-technology company’s blood-oxygen monitoring patent. The decision concludes that Apple’s workout mode and heart rate notification tools violated Masimo’s intellectual property, according to a spokesperson for the company.
Apple says it strongly disagrees with the ruling and will appeal. The tech giant noted that Masimo has pursued more than two dozen patent claims against Apple over the past six years, most of which were deemed invalid. Apple also stressed that the patent at the center of this case expired in 2022 and applies to older, traditional patient-monitoring technology.
Masimo celebrated the verdict, calling it a major step toward protecting its long-standing innovations. The lawsuit is part of a broader legal battle that has intensified tensions between the two companies. Masimo has accused Apple of poaching its employees and misappropriating its pulse oximetry technology for use in Apple Watch models.
The ongoing dispute previously contributed to a U.S. International Trade Commission (ITC) decision that temporarily blocked imports of the Apple Watch Series 9 and Ultra 2 in 2023. The ban was based on findings that Apple’s blood-oxygen technology infringed Masimo’s patents. To sidestep the import halt, Apple removed the pulse-oximetry feature from affected watches and later released an updated version approved by U.S. Customs and Border Protection.
However, the ITC announced it will reassess whether Apple’s updated models should still face restrictions. Masimo has also taken legal action against Customs over its approval decision, while Apple continues to challenge the ITC’s original import ruling in federal court.
This long-running dispute has seen mixed results on both sides. A separate trade-secret trial in California ended in a mistrial in 2023, and Apple won only $250 in a Delaware case claiming Masimo’s devices infringed two Apple design patents.
